<DOC>
	<DOC>NCT00185367</DOC>
	<brief_summary>The aim of this study is to evaluate bleeding pattern, cycle control, and safety of this new four-phasic oral contraceptive in comparison to a reference OC.</brief_summary>
	<brief_title>Comparative Cycle Control Europe</brief_title>
	<detailed_description>The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.</detailed_description>
	<criteria>Healthy female volunteers aged between 18 and 50 years requiring contraception Pregnancy or lactation Any conditions that might interfere with the outcome as well as all contraindications for OC use</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>